Structure Therapeutics' GSBR-1290 showed a placebo-adjusted mean weight loss of 6.2% at 12 weeks, suggesting potential despite initial underwhelming results. Comparatively, Eli Lilly’s orforglipron ...

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...

Structure Therapeutics’ lead drug candidate is chasing big pharmaceutical rivals in the race for new oral weight-loss medications, and the company had been telling investors to expect data late this ...

Seventy years after the invention of a data structure called a hash table, theoreticians have found the most efficient possible configuration for it. About 70 years ago, an engineer at IBM named Hans ...

Eli Lilly is casting a long shadow over the GLP-1 market. Structure Therapeutics linked its oral candidate to significant reductions in blood sugar and weight in a phase 2a trial on Monday, only for ...

Structure Therapeutics CEO Ray Stevens talked about the biotech’s path forward and his expectations for the future of the booming GLP-1 space.

Sept 29 (Reuters) - Shares of Structure Therapeutics (GPCR.O), opens new tab soared 70% on Friday to hit the highest levels since their debut on the Nasdaq as early data from the drug developer's oral ...

In his 1960 book Theory and Design in the First Machine Age, the critic and historian Reyner Banham presciently noted a growing chasm between technological change and the capacity of designers to ...

Structure content for AI search so it’s easy for LLMs to cite. Use clarity, formatting, and hierarchy to improve your visibility in AI results. In the SEO world, when we talk about how to structure ...